Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-9839 in Combination Therapies for Advanced Solid Tumors
NCT06474455Phase 2Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Jul 2024
- Primary completion
- Jun 2029
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-9839 in solid tumor (advanced stage), squamous cell carcinoma of the lung (SCCL), sponsored by Hengrui Therapeutics. Started Jul 2024; status: recruiting.
02
Drugs
SHR-9839
03
Conditions
solid tumor (advanced stage)squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT06474455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06474455.